Press ReleaseView printer-friendly version << Back
vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
In a post hoc analysis of the phase 3 STEADFAST trial, a subgroup of patients with mild Alzheimer’s disease and type 2 diabetes (defined by glycosylated hemoglobin (HbA1c) of greater than 6.5% at any time during the study) who were treated with azeliragon demonstrated a potential benefit in both cognition and function, less brain atrophy and glucose utilization, and decreases in inflammatory biomarkers compared to the same subgroup of patients treated with placebo. Additional details can be found on our publications page.
”We are pleased to announce the initiation of this prospective phase 2 proof of concept study whereby we seek to confirm our findings from the post-hoc analyses of the phase 3 STEADFAST trial,” said
This randomized, double-blind, placebo-controlled, multicenter trial consists of sequential phase 2 and phase 3 studies operationally conducted under one protocol. Each part of the study will evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease (screening MMSE 21 to 26, baseline MMSE 19 to 27; and ADAS-cog14 score ≥10) and type 2 diabetes (screening HbA1c 6.5% to 9.5%, inclusive).
The six-month phase 2 study is designed to enroll approximately 100 patients randomized to either azeliragon 5 mg/day or placebo with the primary endpoint of change from baseline at month 6 in ADAS-cog14. The 18-month phase 3 study, to be initiated following top line results from the phase 2 study, is currently designed to enroll approximately 200 patients with co-primary endpoints of change from baseline at month 18 in cognition and function, subject to modification based upon the phase 2 results. More on the study can be found on www.clinicaltrials.gov under the identifier NCT03980730.
vTv expects to report topline results from the phase 2 proof of concept study by the end of the fourth quarter of 2020.
Azeliragon, also known as TTP488, is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts, RAGE.
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the